SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Ingredients: Top Headlines

API supplier issues again cause FDA to reject Pozen drug candidates

18-Dec-2014 - For the second time the US FDA has rejected two versions of Pozen’s investigational drug candidate because of issues with a supplier’s foreign manufacturing facility.

Related news

News in brief

News in brief

US FDA issues Form 483 to Hovione API facility in Portugal

18-Dec-2014 - The US FDA’s pre-approval inspection at Hovione’s API plant in Loures, Portugal, covering two NDA filings, resulted in a Form 483 with three inspectional observations. 

IPEC-Americas aims to make drug excipient users TUPP aware

15-Dec-2014 - Manufacturers should profile the "black specks" created during excipient production and share details with customers according to guidance finalised by IPEC-Americas, which says the unavoidable particles are starting to earn drugmakers 483s.

AstraZeneca shutting asthma drug plant as pipeline shifts to biologics

12-Dec-2014 - AstraZeneca has continued the Big Pharma trend away from small molecule blockbusters and towards a biologics-heavy pipeline, announcing the closure of its Pulmicort facility in Massachusetts.

Sun closes in on Ranbaxy deal with CCI approval

10-Dec-2014 - The Competition Commission of India (CCI) has approved Sun Pharma’s $3.2bn acquisition of Ranbaxy.

Foreign investment in UK drugmaking down; ABPI tasks ex-GSK exec with reversing trend

10-Dec-2014 - An ex-GSK staffer charged with winning manufacturing investments for the UK says fostering innovation and “fiscal attractiveness” are vital.

Merck & Co set to be superbug-busting superstar despite US Cubicin ruling, analyst

10-Dec-2014 - Cubist will give Merck & Co leadership of the antibiotics sector according to one analyst who says renewed interest expressed by GSK, Roche and Sanofi has not produced any Ph III candidates.

From CPHI India 2014

Indian manufacturing problems spur growth... for testing companies

03-Dec-2014 - SGS has doubled testing capacity at its Mumbai facility, explaining that Indian API makers’ failure to invest in quality has been good for business.

Ingredients: Featured news

Spotlight

Axim to build Dutch facility for cannabinoid-based chewing gum drug

Axim to build Dutch facility for cannabinoid-based chewing gum drug

A company developing a pharmaceutical chewing gum containing cannabinoids extracted from marijuana has announced plans to build...

Two INDs or not two INDs? Unanswered questions in China draft MRCT guide

Two INDs or not two INDs? Unanswered questions in China draft MRCT guide

Drugmakers that include China in multi-regional trials will need to submit dossiers filed elsewhere for review, open...

Advanced aspirin aspirations ailing? Sanofi and Pozen terminate deal

Advanced aspirin aspirations ailing? Sanofi and Pozen terminate deal

Sanofi and Pozen have dissolved a $35m (Eur28m) ‘advanced aspirin’ partnership less than a month before the...

Want to relocate to Asia? What pharma recruiters really look for

Want to relocate to Asia? What pharma recruiters really look for

Singaporean companies are looking for scientists, while China and India need execs – but don’t count on...

Chinese excipient market set to more than double by 2017

Chinese excipient market set to more than double by 2017

With more than 90 excipient manufacturers in China dedicated to the pharma industry, the country expects its...

BASF sells Norway plant, focuses on pharma grade omega-3 products

BASF sells Norway plant, focuses on pharma grade omega-3 products

BASF says the supply of API to GSK and other pharma customers will not be affected by...

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products